The DOI matches its Crossref record; 178 of the 178 references it cites were found in a registry or an index.
A Compressive Review about Taxol®: History and Future Challenges
Open accessAbstract
Taxol®, which is also known as paclitaxel, is a chemotherapeutic agent widely used to treat different cancers. Since the discovery of its antitumoral activity, Taxol® has been used to treat over one million patients, making it one of the most widely employed antitumoral drugs. Taxol® was the first microtubule targeting agent described in the literature, with its main mechanism of action consisting of the disruption of microtubule dynamics, thus inducing mitotic arrest and cell death. However, secondary mechanisms for achieving apoptosis have also been demonstrated. Despite its wide use, Taxol® has certain disadvantages. The main challenges facing Taxol® are the need to find an environmentally sustainable production method based on the use of microorganisms, increase its bioavailability without exerting adverse effects on the health of patients and minimize the resistance presented by a high percentage of cells treated with paclitaxel. This review details, in a succinct manner, the main aspects of this important drug, from its discovery to the present day. We highlight the main challenges that must be faced in the coming years, in order to increase the effectiveness of Taxol® as an anticancer agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
The multilayered complexity of ceRNA crosstalk and competition
Tay, Y., Rinn, J., & Pandolfi, P. P. (2014) · Nature · doi:10.1038/nature12986 · Cited by 3,910
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Exosomes: Extracellular organelles important in intercellular communication
Mathivanan, S., Ji, H., & Simpson, R. J. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.06.006 · Cited by 2,537
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Isoprenoid Pathway Optimization for Taxol Precursor Overproduction in Escherichia coli
Ajikumar, P. K., Xiao, W.-H., Tyo, K. E. J., Wang, Y., Simeon, F., Leonard, E., Mucha, O., Phon, T. H., Pfeifer, B., & Stephanopoulos, G. (2010) · Science · doi:10.1126/science.1191652 · Cited by 1,677
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
How Taxol/paclitaxel kills cancer cells
Weaver, B. A. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0916 · Cited by 1,547
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1413-8 · Cited by 1,269
Rohmer, M., Knani, M., Simonin, P., Sutter, B., & Sahm, H. (1993) · Biochemical Journal · doi:10.1042/bj2950517 · Cited by 1,201
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Paclitaxel and its formulations
Singla, A. K., Garg, A., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100
Nicolaou, K. C., Yang, Z., Liu, J. J., Ueno, H., Nantermet, P. G., Guy, R. K., Claiborne, C. F., Renaud, J., Couladouros, E. A., Paulvannan, K., et al. (1994) · Nature · doi:10.1038/367630a0 · Cited by 1,096
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Rodrı́guez-Concepción, M., & Boronat, A. (2002) · Plant Physiology · doi:10.1104/pp.007138 · Cited by 857
Au Yeung, C. L., Co, N.-N., Tsuruga, T., Yeung, T.-L., Kwan, S.-Y., Leung, C. S., Li, Y., Lu, E. S., Kwan, K., Wong, K.-K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11150 · Cited by 774
Kim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., Kabanov, A. V., & Batrakova, E. V. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.09.011 · Cited by 663
Functional interactions among microRNAs and long noncoding RNAs
Yoon, J.-H., Abdelmohsen, K., & Gorospe, M. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.05.015 · Cited by 655
Kavallaris, M., Kuo, D. Y., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., & Horwitz, S. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119642 · Cited by 601
Emerging roles of lncRNA in cancer and therapeutic opportunities.
Jiang, M., Ni, J., Cui, W., Wang, B., & Zhuo, W. (2019) · PubMed · Cited by 550
Milk-derived exosomes for oral delivery of paclitaxel
Agrawal, A. K., Aqil, F., Jeyabalan, J., Spencer, W. A., Beck, J., Gachuki, B. W., Alhakeem, S. S., Oben, K., Munagala, R., Bondada, S., et al. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2017.03.001 · Cited by 542
Rohmer, M., Seemann, M., Horbach, S., Bringer-Meyer, S., & Sahm, H. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9538344 · Cited by 484
Luo, C., Sun, J., Liu, D., Sun, B., Miao, L., Musetti, S., Li, J., Han, X., Du, Y., Li, L., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b01632 · Cited by 443
Epidermal growth factor receptor inhibition strategies in oncology
Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423
Wanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
The battle of “nano” paclitaxel
Sofias, A. M., Dunne, M., Storm, G., & Allen, C. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.02.003 · Cited by 401
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, O., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395
Engels, B., Dahm, P., & Jennewein, S. (2008) · Metabolic Engineering · doi:10.1016/j.ymben.2008.03.001 · Cited by 378
Régina, A., Demeule, M., Ché, C., Lavallée, I., Poirier, J., Gabathuler, R., Béliveau, R., & Castaigne, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.260 · Cited by 368
Acetals as pH-Sensitive Linkages for Drug Delivery
Gillies, E. R., Goodwin, A. P., & Fréchet, J. M. J. (2004) · Bioconjugate Chemistry · doi:10.1021/bc049853x · Cited by 330
Camptothecin and taxol: Discovery to clinic
Wall, M. E. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199809)18:5<299::aid-med2>3.0.co;2-o · Cited by 330
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
Pusztai, L., Mendoza, T. R., Reuben, J. M., Martinez, M. M., Willey, J. S., Lara, J., Syed, A., Fritsche, H. A., Bruera, E., Booser, D., et al. (2004) · Cytokine · doi:10.1016/j.cyto.2003.10.004 · Cited by 312
SR/ER–mitochondrial local communication: Calcium and ROS
Csordás, G., & Hajnóczky, G. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.06.004 · Cited by 308
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Barbuti, A., & Chen, Z.-S. (2015) · Cancers · doi:10.3390/cancers7040897 · Cited by 269
The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions
Gornstein, E., & Schwarz, T. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.016 · Cited by 252
Engineering microbial factories for synthesis of value-added products
Du, J., Shao, Z., & Zhao, H. (2011) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-011-0970-3 · Cited by 247
Meng, J., Guo, F., Xu, H., Liang, W., Wang, C., & Yang, X.-D. (2016) · Scientific Reports · doi:10.1038/srep22390 · Cited by 236
Biggs, B. W., Lim, C. G., Sagliani, K., Shankar, S., Stephanopoulos, G., De Mey, M., & Ajikumar, P. K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515826113 · Cited by 230
Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis
González-Reyes, S., Marín, L., González, L., González, L. O., del Casar, J. M., Lamelas, M. L., González-Quintana, J. M., & Vizoso, F. J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-665 · Cited by 227
Thomas, F. C., Taskar, K., Rudraraju, V., Goda, S., Thorsheim, H. R., Gaasch, J. A., Mittapalli, R. K., Palmieri, D., Steeg, P. S., Lockman, P. R., et al. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9964-5 · Cited by 226
Docetaxel: A Review of its Use in Metastatic Breast Cancer
Lyseng-Williamson, K. A., & Fenton, C. (2005) · Drugs · doi:10.2165/00003495-200565170-00007 · Cited by 225
Kocher, H. M., Basu, B., Froeling, F. E. M., Sarker, D., Slater, S., Carlin, D., deSouza, N. M., De Paepe, K. N., Goulart, M. R., Hughes, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18636-w · Cited by 217
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway
Strobel, T., Swanson, L., Korsmeyer, S., & Cannistra, S. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14094 · Cited by 216
Chen, D., Zhang, G., Li, R., Guan, M., Wang, X., Zou, T., Zhang, Y., Wang, C., Shu, C., Hong, H., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b12025 · Cited by 211
Symbiotic options for the conquest of land
Field, K. J., Pressel, S., Duckett, J. G., Rimington, W. R., & Bidartondo, M. I. (2015) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2015.05.007 · Cited by 210
MICROTUBULES AS DRUG RECEPTORS: PHARMACOLOGICAL PROPERTIES OF MICROTUBULE PROTEIN*
Wilson, L. (1975) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1975.tb19201.x · Cited by 195
Yang, S., Gursoy, R. N., Lambert, G., & Benita, S. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016238.44452.f1 · Cited by 169
Mikuła-Pietrasik, J., Witucka, A., Pakuła, M., Uruski, P., Begier-Krasińska, B., Niklas, A., Tykarski, A., & Książek, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2954-1 · Cited by 169
How important are Toll-like receptors for antimicrobial responses?
Carpenter, S., & O'Neill, L. A. J. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.00965.x · Cited by 167
Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77
Ferlini, C., Cicchillitti, L., Raspaglio, G., Bartollino, S., Cimitan, S., Bertucci, C., Mozzetti, S., Gallo, D., Persico, M., Fattorusso, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0540 · Cited by 165
TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer
Rajput, S., Volk-Draper, L. D., & Ran, S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1019 · Cited by 165
Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells
Chowdhury, P., Nagesh, P. K. B., Hatami, E., Wagh, S., Dan, N., Tripathi, M. K., Khan, S., Hafeez, B. B., Meibohm, B., Chauhan, S. C., et al. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.09.072 · Cited by 162
An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance
Parker, A. L., Teo, W. S., McCarroll, J. A., & Kavallaris, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071434 · Cited by 158
Conjugated Chitosan as a Novel Platform for Oral Delivery of Paclitaxel
Lee, E., Lee, J., Lee, I., Yu, M., Kim, H., Chae, S. Y., & Jon, S. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800767c · Cited by 157
Do β-tubulin mutations have a role in resistance to chemotherapy?
Berrieman, H. K., Lind, M., & Cawkwell, L. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01411-1 · Cited by 153
Current development in isoprenoid precursor biosynthesis and regulation
Chang, W., Song, H., Liu, H., & Liu, P. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.06.020 · Cited by 150
Liu, X., Ding, W., & Jiang, H. (2017) · Microbial Cell Factories · doi:10.1186/s12934-017-0732-7 · Cited by 147
González‐Reyes, S., Gómez, J. M. F., González, L. O., Aguirre, A., Suárez, A., González, J. M., Escaff, S., & Vizoso, F. J. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0931-0 · Cited by 140
Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment
Chowdhury, M. R., Moshikur, R. M., Wakabayashi, R., Tahara, Y., Kamiya, N., Moniruzzaman, M., & Goto, M. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00305 · Cited by 139
Park, I. H., Sohn, J. H., Kim, S. B., Lee, K. S., Chung, J. S., Lee, S. H., Kim, T. Y., Jung, K. H., Cho, E. K., Kim, Y. S., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.289 · Cited by 133
Zhao, J., Wang, H., Hsiao, C.-H., Chow, D. S., Koay, E. J., Kang, Y., Wen, X., Huang, Q., Ma, Y., Bankson, J. A., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.014 · Cited by 132
Paclitaxel-Dependent Cell Lines Reveal a Novel Drug Activity
Ganguly, A., Yang, H., & Cabral, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0552 · Cited by 130
A New Semisynthesis of Paclitaxel from Baccatin III
Baloglu, E., & Kingston, D. G. I. (1999) · Journal of Natural Products · doi:10.1021/np990040k · Cited by 128
Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma
Pei, Q., Hu, X., Liu, S., Li, Y., Xie, Z., & Jing, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.391 · Cited by 126
Němcová‐Fürstová, V., Kopperová, D., Balušíková, K., Ehrlichová, M., Brynychová, V., Václavíková, R., Daniel, P., Souček, P., & Kovár̆, J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.020 · Cited by 121
Strategies for terpenoid overproduction and new terpenoid discovery
Bian, G., Deng, Z., & Liu, T. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.07.002 · Cited by 120
Xu, S., Wang, P., Zhang, J., Wu, H., Sui, S., Zhang, J., Wang, Q., Qiao, K., Yang, W., Xu, H., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1017-z · Cited by 120
Role of extracellular vesicles in tumour microenvironment
Tao, S., & Guo, S. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00643-5 · Cited by 119
Chen, T., Tu, L., Wang, G., Qi, N., Wu, W., Zhang, W., & Feng, J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119105 · Cited by 114
Maya, S., Kumar, L. G., Sarmento, B. F. C. C., Rejinold, N. S., Menon, D., Nair, S. V., & Jayakumar, R. (2013) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2012.12.032 · Cited by 113
Basic principles of drug delivery systems – the case of paclitaxel
Ezrahi, S., Aserin, A., & Garti, N. (2018) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2018.11.004 · Cited by 113
Development of Lipid-Based Nanoparticles for Enhancing the Oral Bioavailability of Paclitaxel
Pandita, D., Ahuja, A., Lather, V., Benjamin, B., Dutta, T., Velpandian, T., & Khar, R. K. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-011-9636-8 · Cited by 105
Microtubule alterations and resistance to tubulin-binding agents (Review)
Drukman, S., & Kavallaris, M. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.3.621 · Cited by 102
Long non‐coding RNA FTH 1P3 activates paclitaxel resistance in breast cancer through miR‐206/ ABCB 1
Wang, R., Zhang, T., Yang, Z., Jiang, C., & Jingjing, S. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13679 · Cited by 102
Harshita, Barkat, M. A., Beg, S., Pottoo, F. H., & Ahmad, F. J. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0313 · Cited by 102
Wang, Y., Yu, H., Wang, S., Gai, C., Cui, X.-M., Xu, Z., Li, W., & Zhang, W. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111442 · Cited by 102
Advances in exploring alternative Taxol sources
Liu, W.-C., Gong, T., & Zhu, P. (2016) · RSC Advances · doi:10.1039/c6ra06640b · Cited by 97
Alternative sources and metabolic engineering of Taxol: Advances and future perspectives
Sabzehzari, M., Zeinali, M., & Naghavi, M. R. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107569 · Cited by 96
Huang, D., Zhuang, Y., Shen, H. Y., Yang, F., Wang, X., & Wu, D. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.08.063 · Cited by 95
Ren, X., Zhao, B., Chang, H., Xiao, M., Wu, Y., & Liu, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8868 · Cited by 95
Banerjee, A. K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00269-3 · Cited by 94
Liao, S., Zhou, Y., Yuan, Y., Li, D., Wu, F., Wang, Q., Zhu, J., Yan, B., Wei, J., Zhang, G., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1844-0 · Cited by 94
A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors
Zhang, Q., Huang, X., & Gao, L. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.10.001 · Cited by 93
Ding, M., Yan, H.-F., Li, L., Zhai, F., Shang, L., Yin, Z., & Yuan, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109348 · Cited by 93
Hu, J., Fu, S., Peng, Q., Han, Y., Xie, J., Zan, N., Chen, Y., & Fan, J. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.11.047 · Cited by 90
Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions
Micha, J. P., Goldstein, B. H., Birk, C. L., Rettenmaier, M. A., & Brown, J. V. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.012 · Cited by 89
Lee, L., Haskill, J. S., Mukaida, N., Matsushima, K., & Ting, J. P. ‐. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5097 · Cited by 88
UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis
Wang, J., Ye, C., Liu, J., & Hu, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.104 · Cited by 88
Kumar, P., Singh, B., Thakur, V., Thakur, A., Thakur, N., Pandey, D., & Chand, D. (2019) · Biotechnology Reports · doi:10.1016/j.btre.2019.e00395 · Cited by 86
A RubisCO-like protein links SAM metabolism with isoprenoid biosynthesis
Erb, T. J., Evans, B. S., Cho, K., Warlick, B. P. E., Sriram, J., Wood, B., Imker, H. J., Sweedler, J. V., Tabita, F. R., & Gerlt, J. A. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1087 · Cited by 85
Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy
Dong, C., Zhou, Q., Xiang, J., Liu, F., Zhou, Z., & Shen, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.038 · Cited by 85
Mitochondrial permeability transition pore as a selective target for anti-cancer therapy
Suh, D. H., Kim, M.-K., Kim, H. S., Chung, H. H., & Song, Y. S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00041 · Cited by 81
Mevalonate Biosynthesis in Plants
Bach, T. J., Boronat, A., Campos, N., Ferrer, A., & Vollack, K. (1999) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409239991209237 · Cited by 81
Yan, L., Zhao, H., Zhao, X., Xu, X., Di, Y., Jiang, C., Shi, J., Shao, D., Huang, Q., Yang, H., et al. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9101-7 · Cited by 81
Autophagy role(s) in response to oncogenes and DNA replication stress
Vanzo, R., Bartkova, J., Merchut-Maya, J. M., Hall, A., Bouchal, J., Dyrskjøt, L., Frankel, L. B., Gorgoulis, V., Maya-Mendoza, A., Jäättelä, M., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0403-9 · Cited by 79
From taxol to taxol®: The changing identities and ownership of an anti-cancer drug
Walsh, V., & Goodman, J. (2002) · Medical Anthropology · doi:10.1080/01459740214074 · Cited by 79
Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy
Xu, J., Hu, S., Shen, G., & Shen, G. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0290-9 · Cited by 79
Toll-like Receptor 4 Signaling Promotes Tumor Growth
Lee, C., Wu, C., & Shiau, A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b7a0a4 · Cited by 78
Du, X., Yin, S., Xu, L., Ma, J., Yu, H., Wang, G., & Li, J. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115484 · Cited by 78
Duan, F., Wang, M., Cao, Y., Li, D., Li, R.-Z., Fan, X., Khan, I., Lai, H., Zhang, Y., Hsiao, W. L. W., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2031-1 · Cited by 78
Nanocarriers in cancer clinical practice: a pharmacokinetic issue
Giodini, L., Re, F. L., Campagnol, D., Marangon, E., Posocco, B., Dreussi, E., & Toffoli, G. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.07.012 · Cited by 77
Sun, H., Zhu, A.-Y., Zhou, X., & Wang, F. (2017) · Oncotarget · doi:10.18632/oncotarget.16991 · Cited by 77
Abriata, J. P., Turatti, R. C., Luiz, M. T., Raspantini, G. L., Tofani, L. B., do Amaral, R. L. F., Swiech, K., Marcato, P. D., & Marchetti, J. M. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.11.035 · Cited by 77
Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts
Ye, L., He, J., Hu, Z., Dong, Q., Wang, H., Fu, F., & Tian, J. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.11.004 · Cited by 76
Zhang, D., & Kanakkanthara, A. (2020) · Cancers · doi:10.3390/cancers12071721 · Cited by 75
Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells
WANG, A.-C., Su, Q. B., Wu, F. X., Zhang, X., & Liu, P. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02070.x · Cited by 74
Wu, H., Chen, S., Yu, J., Li, Y., Zhang, X., Yang, L., Zhang, H., Hou, Q., Jiang, M., Brunicardi, F. C., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.059 · Cited by 74
Zhou, L., Lv, F., Liu, L., Shen, G., Yan, X., Bazan, G. C., & Wang, S. (2018) · Advanced Materials · doi:10.1002/adma.201704888 · Cited by 74
Targeting miRNAs by natural products: A new way for cancer therapy
Zhang, B., Tian, L., Xie, J., Chen, G., & Wang, F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110546 · Cited by 73
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein
Weidner, L. D., Fung, K.-L., Kannan, P., Moen, J. K., Kumar, J. S., Mulder, J., Innis, R. B., Gottesman, M. M., & Hall, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067785 · Cited by 70
Xia, D., Yu, H., Tao, J., Zeng, J., Zhu, Q., Zhu, C., & Gan, Y. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.01.047 · Cited by 70
White, C. M., Martin, B. K., Lee, L., Haskill, J. S., & Ting, J. P. ‐. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050468 · Cited by 69
Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells
Zheng, A.-W., Chen, Y., Zhao, L., & Feng, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6031 · Cited by 68
Yang, M., Wang, B., Gao, J., Zhang, Y., Xu, W., & Tao, L. (2016) · Chemosphere · doi:10.1016/j.chemosphere.2016.11.065 · Cited by 67
Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer
Yang, N., Wang, C., Wang, J., Wang, Z., Huang, D., Yan, M., Muhammad, K. I., Liu, Q., & Xu, B. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14538 · Cited by 66
Predicting lncRNA-miRNA Interaction via Graph Convolution Auto-Encoder
Huang, Y., Huang, Z.-A., You, Z., Zhu, Z., Huang, W., Guo, J., & Yu, C.-Q. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00758 · Cited by 65
Bomane, A., Gonçalvès, A., & Ballester, P. J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01041 · Cited by 65
Mu, J., Zhong, H., Zou, H., Liu, T., Yu, N., Zhang, X., Xu, Z., Chen, Z., & Guo, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.022 · Cited by 65
Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India
Ranade, A. A., Joshi, D. A., Phadke, G. K., Patil, P. P., Kasbekar, R. B., Apte, T. G., Dasare, R. R., Mengde, S. D., Parikh, P. M., Bhattacharyya, G. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt322 · Cited by 64
Ly, S., Zhang, Y., Wang, W., Sui, X., Liu, S.-K., Wang, T., & Zhang, H. (2016) · PubMed · Cited by 63
Penfluridol overcomes paclitaxel resistance in metastatic breast cancer
Gupta, N., Gupta, P., & Srivastava, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41632-0 · Cited by 63
Li, X., Han, X., Wei, P., Yang, J., & Sun, J. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1727700 · Cited by 63
Developments in taxol production through endophytic fungal biotechnology: a review
Naik, B. S. (2018) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-018-0352-8 · Cited by 62
Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells
Borys, F., Joachimiak, E., Krawczyk, H., & Fabczak, H. (2020) · Molecules · doi:10.3390/molecules25163705 · Cited by 60
El‐Sayed, A. S. A., Ali, D. M. I., Yassin, M. A., Zayed, R., & Ali, G. S. (2018) · Process Biochemistry · doi:10.1016/j.procbio.2018.10.008 · Cited by 59
Lu, C., Xie, Z., & Peng, Q. (2017) · PubMed · Cited by 57
Polysaccharide-based Noncovalent Assembly for Targeted Delivery of Taxol
Yang, Y., Zhang, Y., Chen, Y., Chen, J., & Liu, Y. (2016) · Scientific Reports · doi:10.1038/srep19212 · Cited by 56
Choudhury, H., Gorain, B., Tekade, R. K., Pandey, M., Karmakar, S., & Pal, T. K. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.10.023 · Cited by 56
Hou, L., Zhao, Y., Song, G., Ma, Y., Jin, X., Jin, S., Fang, Y.-H., & Chen, Y.-C. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0904-0 · Cited by 55
Akasaka, K., Maesawa, C., Shibazaki, M., Maeda, F., Takahashi, K., Akasaka, T., & Masuda, T. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.406 · Cited by 52
Transcriptomic Analysis of mRNA-lncRNA-miRNA Interactions in Hepatocellular Carcinoma
Tang, X., Feng, D., Li, M., Zhou, J., Li, X., Zhao, D., Hao, B., Li, D., & Ding, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-52559-x · Cited by 52
Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer
He, D.-X., Gu, F., Gao, F., Hao, J.-J., Gong, D., Gu, X.-T., Mao, A.-Q., Jin, J., Fu, L., & Ma, X. (2016) · Scientific Reports · doi:10.1038/srep24706 · Cited by 51
The miR-195 Axis Regulates Chemoresistance through TUBB and Lung Cancer Progression through BIRC5
Yu, X., Zhang, Y., Wu, B., Kurie, J. M., & Pertsemlidis, A. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.07.004 · Cited by 51
Huang, C., Zhang, X., Jiang, L., Zhang, L., Xiang, M., & Ren, H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.05.005 · Cited by 50
Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer
Abildgaard, C., do Canto, L. M., Steffensen, K. D., & Rogatto, S. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01549 · Cited by 50
Chowdhury, M. R., Moshikur, R. M., Wakabayashi, R., Tahara, Y., Kamiya, N., Moniruzzaman, M., & Goto, M. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.020 · Cited by 48
MicroRNA‐193a and taxol combination: A new strategy for treatment of colorectal cancer
Hejazi, M., Baghbani, E., Amini, M. A., Rezaei, T., Aghanejad, A., Mosafer, J., Mokhtarzadeh, A., & Baradaran, B. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29374 · Cited by 48
LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1
Shi, C., & Wang, M. (2018) · Medical Science Monitor · doi:10.12659/msm.910932 · Cited by 47
Gill, H., & Vasundhara, M. (2019) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-019-2651-8 · Cited by 47
Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms
Aldonza, M. B. D., Ku, J., Hong, J., Kim, D., Yu, S. J., Lee, M.-S., Prayogo, M. C., Tan, S., Kim, D., Han, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aav7416 · Cited by 47
Zhao, Y., Han, M., Xiong, Y., Wang, L., Fei, Y., Shen, X., Zhu, Y., & Liang, Z. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.164 · Cited by 46
Redox responsive paclitaxel dimer for programmed drug release and selectively killing cancer cells
Xia, R., Pei, Q., Wang, J., Wang, Z., Hu, X., & Xie, Z. (2020) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.07.086 · Cited by 46
MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression
Tang, X., Jin, L., Cao, P., Cao, K., Huang, C., Luo, Y., Ma, J., Shen, S., Tan, M., Li, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8056 · Cited by 45
Zhao, H., Wang, A., & Zhang, Z. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa036 · Cited by 45
Ingle, S. G., Pai, R. V., Monpara, J. D., & Vavia, P. R. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.06.025 · Cited by 44
Liu, S., Zou, B., Tian, T., Luo, X., Mao, B., Zhang, X., & Lei, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28032 · Cited by 44
KRT17 confers paclitaxel-induced resistance and migration to cervical cancer cells
Li, J., Chen, Q., Deng, Z., Chen, X., Liu, H., Ying, T., Wang, X., Lin, S., & Liu, N. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.065 · Cited by 44
Lv, Y., Cang, W., Li, Q., Liao, X., Zhan, M., Deng, H., Li, S., Jin, W., Pang, Z., Qiu, X., et al. (2019) · Oncogenesis · doi:10.1038/s41389-019-0179-2 · Cited by 44
Tan, Q., Joshua, A. M., Wang, M., Bristow, R. G., Wouters, B. G., Allen, C. J., & Tannock, I. F. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3298-5 · Cited by 43
Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells
Xu, J., Wu, J., Fu, C., Teng, F., Liu, S., Dai, C., Shen, R., & Jia, X. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26369 · Cited by 43
Liu, Y., Gao, S., Chen, X., Liu, M., Mao, C., & Fang, X. (2016) · Tumor Biology · doi:10.1007/s13277-016-5066-2 · Cited by 41
Glutathione-responsive paclitaxel dimer nanovesicles with high drug content
Pei, Q., Hu, X., Zhou, J., Liu, S., & Xie, Z. (2017) · Biomaterials Science · doi:10.1039/c7bm00052a · Cited by 41
Gu, M., Zheng, W., Zhang, M., Dong, X., Zhao, Y., Wang, S., Jiang, H., & Zheng, X. (2020) · Journal of Cancer · doi:10.7150/jca.39463 · Cited by 41
Zhai, Y., Zhou, X. W., Jia, L., Ma, C., Rong-hua, S., Deng, Y., Hu, X., & Sun, W. (2017) · Polymers · doi:10.3390/polym9120698 · Cited by 39
Christoph, D. C., Kasper, S., Gauler, T. C., Loesch, C., Engelhard, M., Theegarten, D., Poettgen, C., Hepp, R., Peglow, A., Loewendick, H., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.324 · Cited by 36
Chemotherapeutic Agent Paclitaxel Mediates Priming of NLRP3 Inflammasome Activation
Son, S., Shim, D.-W., Hwang, I., Park, J., & Yu, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01108 · Cited by 36
Borgå, O., Henriksson, R., Bjermo, H., Lilienberg, E., Heldring, N., & Loman, N. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00909-6 · Cited by 35
Bai, Z., Ding, N., Ge, J., Wang, Y., Wang, L., Wu, N., Wei, Q., Xu, S., Liu, X., & Zhou, G. (2020) · Cell Biology International · doi:10.1002/cbin.11481 · Cited by 35
Li, L., Wu, C., & Zhao, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6041 · Cited by 34
miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1
Huang, L., Hu, C., Chao, H., Wang, R., Lu, H., Li, H., & Chen, H. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.02.012 · Cited by 34
Zhang, M., Asghar, S., Jin, X., Hu, Z., Ping, Q. N., Chen, Z., Shao, F., & Xiao, Y. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.07.114 · Cited by 32
Tumor-specific delivery of a paclitaxel-loading HSA-haemin nanoparticle for cancer treatment
Chung, H., Kim, H., & Hong, S. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102089 · Cited by 32
Chen, J., Zhu, M.-Q., Liqiu, Z., Xia, J., Huang, J., Deng, Q., & Xu, R. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa072 · Cited by 32
Wang, W., Zhang, H., Wang, X., Patterson, J., Winter, P., Graham, K., Ghosh, S., Lee, J. C., Katsetos, C. D., Mackey, J. R., et al. (2016) · PROTOPLASMA · doi:10.1007/s00709-016-1060-1 · Cited by 28
El‐Araby, M. E., Omar, A. M., Khayat, M. T. A., Assiri, H. A., & Al-Abd, A. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168938 · Cited by 28
Paclitaxel induces autophagy in gastric cancer BGC823 cells
Yu, Y., Hu, P., Wang, Y., Xu, X., Rushworth, G.-M., Zhang, Z., Wei, L., & Zhang, J. (2017) · Ultrastructural Pathology · doi:10.1080/01913123.2017.1334019 · Cited by 26
FNDC5 promotes paclitaxel sensitivity of non-small cell lung cancers via inhibiting MDR1
Fan, G.-H., Zhu, T.-Y., & Huang, J. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109665 · Cited by 26
Wang, B., Li, S., Meng, X., Shang, H., & Guan, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3333-2 · Cited by 22
Li, M., Yin, L.-M., Wu, L. J., Zhu, Y., & Wang, X. (2020) · Molecular & Cellular Toxicology · doi:10.1007/s13273-020-00093-7 · Cited by 22
Jang, Y., Ko, M. K., Park, Y. E., Hong, J. W., Lee, I., Chung, H. J., & Chung, H. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.09.014 · Cited by 18
Rieder, C. L., & Medema, R. H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.021 · Cited by 17
Shen, Y., Zhang, X.-Y., Chen, X., Fan, L., Ren, M., Wu, Y.-P., Chanda, K., & Jiang, S. (2016) · Oncology Reports · doi:10.3892/or.2016.5260 · Cited by 12
An ATG5 knockout promotes paclitaxel resistance in v-Ha-ras-transformed NIH 3T3 cells
Eom, S. Y., Hwang, S., Yeom, H., & Lee, M. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.197 · Cited by 11
PEG-derivatized birinapant as a nanomicellar carrier of paclitaxel delivery for cancer therapy
Shu, X., Zhu, Z., Cao, D., Zheng, L., Wang, F., Pei, H., Wen, J., Yang, J., Li, D., Bai, P., et al. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110356 · Cited by 10
Ma, W. W., Lam, E. T., Dy, G. K., Diamond, J. R., Zhao, Y., Bui, L. A., Fetterly, G. J., Abramowitz, W., Harning, R., Pencheva, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2557 · Cited by 4
Cited by
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Regulation of microtubule dynamics, mechanics and function through the growing tip
Gudimchuk, N. B., & McIntosh, J. R. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00399-x · Cited by 369
Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics
Wei, D., Sun, Y., Zhu, H., & Fu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.3c06019 · Cited by 303
El-Gendi, H., Saleh, A. K., Badierah, R., Redwan, E. M., El-Maradny, Y. A., & El-Fakharany, E. M. (2021) · Journal of Fungi · doi:10.3390/jof8010023 · Cited by 285
Zhang, C., Chen, W., Dong, T., Wang, Y., Yao, M., Xiao, W., & Li, B. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1141272 · Cited by 16
Metadata
- Authors
- Gallego-Jara, J., Lozano-Terol, G., Sola-Martínez, R. A., Cánovas-Díaz, M., & de Diego Puente, T.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-17
- Volume
- 25
- Issue
- 24
- Pages
- 5986
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3110830766
- Cited by
- 344
- References
- 178
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.